- Home
- XYF vs KROS Comparison
XYF vs KROS Comparison
Compare XYF & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XYF | KROS |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | China | United States |
| Employees | N/A | 87 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.4M | 222.3M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | XYF | KROS |
|---|---|---|
| Price | $4.89 | $11.32 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.86 |
| AVG Volume (30 Days) | 133.3K | ★ 322.7K |
| Earning Date | 05-18-2026 | 05-06-2026 |
| Dividend Yield | ★ 11.34% | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,751.79 |
| P/E Ratio | $0.90 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.30 | $9.79 |
| 52 Week High | $20.36 | $22.55 |
Technical Indicators
Market Signals| Indicator | XYF | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 53.62 | 50.53 |
| Support Level | $4.86 | $10.47 |
| Resistance Level | $5.12 | $12.43 |
| Average True Range (ATR) | 0.31 | 0.69 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 67.33 | 65.08 |
Price Performance
Historical ComparisonAbout XYF X Financial each representing six
X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, and guarantee services provided.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.